Medicine
Glyrx-pf 0.6 mg/3 mL injection
Glyrx-pf 0.6 mg/3 mL injection is a prescription medicine containing Glycopyrrolate for intramuscular, intravenous use, marketed by Exela Pharma Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Glycopyrrolate
- Brand
- Glyrx-pf
- Strength
- 0.6 mg/3 mL
- Dosage form
- Injection
- Route
- Intramuscular, intravenous
- Packs
- 10 syringes of 3 mL
- Marketing authorisation holder
- Exela Pharma Sciences
- Manufacturer
- Exela Pharma Sciences
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A03AB02 Glycopyrrolate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 June 2020
- Identifiers
- RxCUI 1731582, 1731590, 2371710 +5DailyMed set ID 2189f3f5-39dc-4e85-b7c6-9515ded59686NDC 51754-6013Application NDA210997
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 51754-6013-3 | Exela Pharma Sciences | 15 December 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 11 August 1961 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Glycopyrrolate 0.6 mg/3 mL injection.
Other strengths and forms of Glycopyrrolate
Clinical summary
Glycopyrrolate is an anticholinergic indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer, among other approved uses. MedsAcross supplies Glycopyrrolate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GlycopyrrolateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Glycopyrrolate prescribing information (Rising Pharma Holdings) · U.S. National Library of Medicine, DailyMed
Need Glyrx-pf 0.6 mg/3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.